Vildan Özkocaman

Exploratory Analysis of the C-Reactive Protein–Albumin–Lymphocyte Index and Progression-Free Survival in Early-Stage Classical Hodgkin Lymphoma

An easily accessible biomarker to predict early relapse in early-stage classical Hodgkin lymphoma (cHL) remains an unmet clinical need, and this study explored whether the C-reactive protein–albumin–lymphocyte (CALLY) index provides prognostic information in this setting. Ninety-...